Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02550613
NCT02550613
Unknown
Not Applicable

Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

National Taiwan University Hospital1 site in 1 country100 target enrollmentMay 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHepatocellular Carcinoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hepatocellular Carcinoma
Sponsor
National Taiwan University Hospital
Enrollment
100
Locations
1
Primary Endpoint
The recurrence rate at 3 months after treatment
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.

Detailed Description

This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
April 2018
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Prior Informed Consent Form
  • •At least one measurable tumor, according to RECIST version 1.
  • •Age \> 20 years.
  • •ECOG performance status 0 or
  • •Life expectancy \> 3 months.
  • •Confirmed Diagnosis of HCC
  • •Adequate renal function (Serum creatinine ≦ 1.5 x upper limit of normal).

Exclusion Criteria

  • •Age \<20 years old
  • •Contraindication for MRI: claustrophobia or MR non-compatible devices
  • •Contraindication for MR contrast medium: severe adverse reaction or impaired renal function (Cre \> 2.0)
  • •History of other malignancy

Outcomes

Primary Outcomes

The recurrence rate at 3 months after treatment

Time Frame: 3 months

Secondary Outcomes

  • The overall survival after treatment(1 year)

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic CancerPancreatic Cancer
NCT02550847National Taiwan University Hospital100
Terminated
Not Applicable
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical CancerCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedCervical Undifferentiated CarcinomaRecurrent Cervical CarcinomaStage IB2 Cervical CancerStage II Cervical CancerStage IIA Cervical CancerStage IIB Cervical CancerStage III Cervical CancerStage IIIA Cervical CancerStage IIIB Cervical CancerStage IVA Cervical Cancer
NCT01992861University of Washington51
Completed
Not Applicable
Clinical Evaluation of an Integrated PET/MRI SystemSubjects With Clinical Indication for PET/CT
NCT02071706GE Healthcare62
Completed
Not Applicable
Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility StudyIBD
NCT02364973Turku University Hospital20
Completed
Not Applicable
Role of PET/MRI in Head and Neck CancerHead and Neck CancerBenign NeoplasmMalignant Neoplasm
NCT04360993University of Pecs110